carisbamate

Also known as RWJ-333369, (S)-carisbamate, YKP-509, Comfyde

Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.

In the Vinony graph

Vinony's link graph records 563 inbound references to carisbamate, and connects out to benzodiazepine drug, alphenal and acylurea.

It sits within the topics 2-Chlorophenyl compounds, Abandoned drugs and Anticonvulsants.

Vinony links it to 5 Wikipedia language editions.

Chemical data

Formula: C9H10ClNO3
Molecular weight: 215.63 g/mol
IUPAC name: [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate
SMILES: C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl
InChIKey: OLBWFRRUHYQABZ-MRVPVSSYSA-N
XLogP: 1
Polar surface area: 72.6 Å²
H-bond donors: 2
H-bond acceptors: 3
Formal charge: 0

via PubChem

Wikidata facts

Subclass of: chemical compound
Mass: 215.03492086

Show 3 more facts

isomeric SMILES: C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl
chemical formula: C₉H₁₀ClNO₃
canonical SMILES: NC(=O)OCC(O)c1ccccc1Cl

Sources (2)

via Wikidata · CC0

~2 min read

Encyclopedic overview

3 sections

Contents

Clinical study
History
References

Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.

==Clinical study== A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.

Excerpted from Wikipedia’s “carisbamate” article, available under the CC BY-SA 4.0 licence.